Infusion and specialty pharmacies have been playing a critical role in navigating a frequently changing menu of infused monoclonal antibody therapies authorized for COVID-19 patients.
The process began on Nov. 9, 2020, when the FDA issued an emergency use authorization (EUA) for bamlanivimab (LY-CoV555, Lilly) for the treatment of mild to moderate COVID-19. One of the first pharmacies to begin providing bamlanivimab was the pharmacy of Nebraska Medicine, in Omaha, the primary